Presentation is loading. Please wait.

Presentation is loading. Please wait.

Off-label Promotion: Managing the Regulatory Risks

Published byBartholomew Austin Modified over 6 years ago

Similar presentations

Presentation on theme: "Off-label Promotion: Managing the Regulatory Risks"— Presentation transcript:

1 Off-label Promotion: Managing the Regulatory Risks
Pharma Congress 2003 National Audio conference October 2, 2003 Michael Misocky, R.Ph., J.D.

2 Off-label Promotion What is it? Know it when you see it!
Inconsistent with or contrary to approved product labeling (includes but not limited to indications for use, dosing, special patient populations)

3 Off-label Promotion When is it not “promotion”?
Scientific Exchange (see 21 CFR 312.7) (could include press releases, scientific reprints, and medical education) Unsolicited requests Safe harbors (Independence Criteria for CME and FDAMA Section 401 or 21 CFR Part 99)

4 Off-Label Promotion What are the regulatory and other risks?
FDA Warning or Untitled Letters (could warrant corrective campaign) Mandatory preclearance (of all promotional materials) Dept of Justice Civil or Criminal Proceedings (for misbranding) Class Action Lawsuits False Claims Act (Medicaid Fraud)

5 Off-label Promotion Managing the risks
Get a handle on “all” activities (concerted campaign) Review training materials (similar rigor and scrutiny as promotional materials) Find a safe harbor and dock there First amendment protection for scientific reprint dissemination Mandatory promotional compliance training program

Download ppt "Off-label Promotion: Managing the Regulatory Risks"

Similar presentations

Prosecutorial Perspective on Off- Label Promotion Virginia Gibson Assistant U.S. Attorney National Pharma AudioConference, October 26, 2004.

Prosecutorial Perspective on Off- Label Promotion Virginia Gibson Assistant U.S. Attorney National Pharma AudioConference, October 26, 2004.
FDA Regulation of the Dissemination of Medical Device Information

FDA Regulation of the Dissemination of Medical Device Information
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.

An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.

The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.
Virginia State Bar Annual Meeting Corporate Counsel Section Update on Do Not Call & Spam Michael Goodman Federal Trade Commission www.ftc.gov.

Virginia State Bar Annual Meeting Corporate Counsel Section Update on Do Not Call & Spam Michael Goodman Federal Trade Commission
Determining the Regulatory Pathway to Market Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Regulatory Off-Label Communications Conference © 2011 Fox Rothschild Exploring the Nature of Scrutiny Surrounding Off-Label Information December 6, 2011.

Regulatory Off-Label Communications Conference © 2011 Fox Rothschild Exploring the Nature of Scrutiny Surrounding Off-Label Information December 6, 2011.
@ PMCQ U October 19, 2004. Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.

@ PMCQ U October 19, Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.
PDUFA and DTC Advertising Reviews Prior to Use Public Hearing February 16, 2007 Testimony of the Coalition for Healthcare Communication.

PDUFA and DTC Advertising Reviews Prior to Use Public Hearing February 16, 2007 Testimony of the Coalition for Healthcare Communication.
FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,

FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,
510k Submission Overview Myraqa, Inc. August 22, 2012.

510k Submission Overview Myraqa, Inc. August 22, 2012.
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.

Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
RAC Study Group Chapter 16

RAC Study Group Chapter 16
FDA Tobacco Regulations. During the 90’s  1998 Master Settlement Agreement  Tobacco companies charged.

FDA Tobacco Regulations. During the 90’s  1998 Master Settlement Agreement  Tobacco companies charged.
Special Topics in IND Regulation

Special Topics in IND Regulation
May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.

May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.

Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
November, 2004 Slide 1 FDA PROMOTIONAL RULES The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Arthur N. Levine.

November, 2004 Slide 1 FDA PROMOTIONAL RULES The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Arthur N. Levine.
Division of Drug Marketing, Advertising, and Communications Enforcement Webinar Sangeeta Vaswani Chatterjee, Regulatory Counsel Team Leader Marissa Chaet.

Division of Drug Marketing, Advertising, and Communications Enforcement Webinar Sangeeta Vaswani Chatterjee, Regulatory Counsel Team Leader Marissa Chaet.

Similar presentations

Ads by Google